Purple Biotech Ltd ADR (PPBT)

$0.85 +0.06 (8.17%)
Market Cap 10.42M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 303,700
Avg Vol 9,004,798
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 75%
Beta 0.60
Analysts Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Stocksavior14
Stocksavior14 Dec. 5 at 2:51 AM
$PPBT amen..
0 · Reply
revuelto
revuelto Dec. 5 at 12:23 AM
$PPBT it’s a poster presentation at esmo, no oral, no proffered i.e. zero interest from real money…if it pumps, dump it fast…gl ✌️
1 · Reply
purpdaddy
purpdaddy Dec. 4 at 7:13 PM
$PPBT 🚀
0 · Reply
Stocksavior14
Stocksavior14 Dec. 4 at 5:56 PM
$PPBT ANOTHER pre-clinical drug because they need to have MORE EXCUSES to dilute since they make $0, pay themselves MASSIVELY, and run this terribly… So how can we afford the more and more drugs they want to keep trying without making ANY MONEY??🤣🤣🤣 Man they want to keep this corruption going as long as possible. Get ready for another REVERSE SPLIT… they will need to do it in order to dilute more🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Dec. 4 at 5:30 PM
$PPBT that’s cause they aren’t going to be able to go much further with the other drugs since we are basically broke LOL
0 · Reply
SirGay_LoveRaw
SirGay_LoveRaw Dec. 4 at 4:55 PM
$PPBT LOL, yet another preclinical? They really want to keep the show going as long as possible, to continue paving their way to cozy retirements with investors money
1 · Reply
FBP
FBP Dec. 4 at 2:54 PM
$PPBT If I had a nickel for every time they pr a new preclinical..
1 · Reply
Lasvegasguy12
Lasvegasguy12 Dec. 4 at 2:47 PM
$PPBT oh look! Another scam drug to keep the scam going.
0 · Reply
YamiDawg
YamiDawg Dec. 4 at 1:51 PM
$PPBT Preclinical PPBT is fake science. DD preclinical NT219. Preclinical CM24. Both cure cancer. NT219 save the world. Made every drug combo better. Touted made number 1 drug Keytruda over 40% better. Cured cancer in Apes and Mice. Now after phase 1-2 trials where is it. At a Colorado college. Zero collaborators or partners. DD Inbal Greenberg PPBT. CM24 once Merk paid $605 million for it. Put in phase 1 trials and pulled it sold it. KTOV ppbt got it and DD all the spectacular publications. Once we had BMY as a collaborator but after a fake out phase 2 trials conducted full well aware they were not making or fulfilling the requirements. Fraud basically against investors. PPBT now has to claim phase 2b. No such thing. It’s phase to repeat. lol. BMY is out and again this alleged miracle drug zero collaborators or partners. If they were as good as advertised. Do you honestly believe no deals. Reason we never made a dime and RS RC almost yearly.
2 · Reply
for656
for656 Dec. 4 at 1:33 PM
$PPBT
0 · Reply
Latest News on PPBT
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Dec 4, 2025, 7:00 AM EST - 17 hours ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 14, 2025, 8:00 AM EST - 20 days ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 29, 2025, 7:33 AM EDT - 5 weeks ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 20, 2025, 4:00 PM EDT - 6 weeks ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 3 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 4 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 7 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 7 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 7 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 9 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 10 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Stocksavior14
Stocksavior14 Dec. 5 at 2:51 AM
$PPBT amen..
0 · Reply
revuelto
revuelto Dec. 5 at 12:23 AM
$PPBT it’s a poster presentation at esmo, no oral, no proffered i.e. zero interest from real money…if it pumps, dump it fast…gl ✌️
1 · Reply
purpdaddy
purpdaddy Dec. 4 at 7:13 PM
$PPBT 🚀
0 · Reply
Stocksavior14
Stocksavior14 Dec. 4 at 5:56 PM
$PPBT ANOTHER pre-clinical drug because they need to have MORE EXCUSES to dilute since they make $0, pay themselves MASSIVELY, and run this terribly… So how can we afford the more and more drugs they want to keep trying without making ANY MONEY??🤣🤣🤣 Man they want to keep this corruption going as long as possible. Get ready for another REVERSE SPLIT… they will need to do it in order to dilute more🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Dec. 4 at 5:30 PM
$PPBT that’s cause they aren’t going to be able to go much further with the other drugs since we are basically broke LOL
0 · Reply
SirGay_LoveRaw
SirGay_LoveRaw Dec. 4 at 4:55 PM
$PPBT LOL, yet another preclinical? They really want to keep the show going as long as possible, to continue paving their way to cozy retirements with investors money
1 · Reply
FBP
FBP Dec. 4 at 2:54 PM
$PPBT If I had a nickel for every time they pr a new preclinical..
1 · Reply
Lasvegasguy12
Lasvegasguy12 Dec. 4 at 2:47 PM
$PPBT oh look! Another scam drug to keep the scam going.
0 · Reply
YamiDawg
YamiDawg Dec. 4 at 1:51 PM
$PPBT Preclinical PPBT is fake science. DD preclinical NT219. Preclinical CM24. Both cure cancer. NT219 save the world. Made every drug combo better. Touted made number 1 drug Keytruda over 40% better. Cured cancer in Apes and Mice. Now after phase 1-2 trials where is it. At a Colorado college. Zero collaborators or partners. DD Inbal Greenberg PPBT. CM24 once Merk paid $605 million for it. Put in phase 1 trials and pulled it sold it. KTOV ppbt got it and DD all the spectacular publications. Once we had BMY as a collaborator but after a fake out phase 2 trials conducted full well aware they were not making or fulfilling the requirements. Fraud basically against investors. PPBT now has to claim phase 2b. No such thing. It’s phase to repeat. lol. BMY is out and again this alleged miracle drug zero collaborators or partners. If they were as good as advertised. Do you honestly believe no deals. Reason we never made a dime and RS RC almost yearly.
2 · Reply
for656
for656 Dec. 4 at 1:33 PM
$PPBT
0 · Reply
Duediligence20
Duediligence20 Dec. 4 at 1:30 PM
$PPBT We don’t care about “preclinical data” regarding CAPTN-3 we care about continuation of trials for NT-219, and CM-24. What don’t you clowns get? Preclinical stuff screams Dilution, evaluation we are stalled out stage 3 and stage 2 on compounds that showed significant promise that could help SP recover. You either have something or don’t. Stay in the game or stop scamming people and fleecing them of hard earned money.
0 · Reply
Stocksavior14
Stocksavior14 Dec. 4 at 1:14 PM
$PPBT oh look you’re still here. Hows being super bullish and having your shares divided by 200 and heading towards another reverse split to divide them more working out for you??🤣🤣
1 · Reply
coinspitter
coinspitter Dec. 4 at 12:27 PM
$PPBT bullish on the science, bearish on management!
0 · Reply
Mighty777
Mighty777 Dec. 4 at 12:19 PM
$PPBT
0 · Reply
Avharju
Avharju Dec. 4 at 12:02 PM
$PPBT https://www.pressviewer.com/ViewEmail.asp?b=2492&id=374459&p=2412439&I=1294115-j2a5l2c7y4
0 · Reply
Limitlesstocks
Limitlesstocks Dec. 4 at 8:52 AM
$PPBT cocksavior is still posting 😂
0 · Reply
Stocksavior14
Stocksavior14 Dec. 3 at 9:23 PM
$PPBT they permabulls would offer to buy you some, but they are too ultra bullish on being poor losing everything here
0 · Reply
LetItRip675
LetItRip675 Dec. 3 at 5:30 PM
$PPBT I need a cigarette
0 · Reply
LuckyBoy27
LuckyBoy27 Dec. 3 at 4:22 PM
$PPBT wtf our stupid management doing. Rearranging PPT slides for next pump & Dump 👇
1 · Reply
Stocksavior14
Stocksavior14 Dec. 3 at 2:48 PM
$PPBT permabulls getting their circle jerk going knowing they will get a 3rd super bullish reverse split on the horizon🤣🤣
0 · Reply
Stocktelligence
Stocktelligence Dec. 3 at 2:31 PM
$PPBT capr damn 💥 That’s how violent it can be
1 · Reply
JL_TradeZ
JL_TradeZ Dec. 3 at 2:31 AM
Worth keeping an eye on for tomorrow $PPBT is holding up nicely with a small float and high short interest. Sitting right under the breakout area and can move quickly if volume shows up. $QTTB still has elevated volume and a small float. Watching for a break of 3.55-3.60, but only if it gets some strength during the open.
0 · Reply